SAHMRI and Trajan Nutrition sign new agreement to accelerate nutrition testing worldwide

SAHMRI and Trajan Nutrition sign new agreement to accelerate nutrition testing worldwide

February 17, 2020

Adelaide, South Australia, Australia

Trajan Nutrition has signed a Memorandum of Understanding with the South Australian Health and Medical Research Institute (SAHMRI) to accelerate the translation in the global market of nutrition testing research led by professors Maria Makrides and Robert Gibson.

Trajan Scientific and Medical established Trajan Nutrition in 2017 as a joint venture with Prof Makrides and Prof Gibson, and recently appointed Mr Marco Baccanti as CEO.

Mr Baccanti, CEO of Trajan Nutrition, comments, “This new agreement will support Trajan Nutrition in offering tailored solutions and technologies for nutrition testing on a global scale; in partnership with research organisations, pathology laboratories, food and supplement companies, health insurance and corporate wellness providers.”

Under the new agreement, Trajan Nutrition and SAHMRI will leverage the know-how and the expertise of the SAHMRI Nutrition Laboratory, an analytical testing and research laboratory entirely dedicated to nutrition tests, perhaps the biggest and best-equipped in the Asia Pacific region. 

Professor Steve Wesselingh, Executive Director of SAHMRI, said, “This agreement with Trajan Nutrition is an important example of SAHMRI’s strategy to deliver translation of the results of its medical research activities into therapeutic solutions for patients, and better preventative health approaches.”

Trajan Scientific and Medical enriches the wellbeing of a growing number of communities through improved scientific and medical tools and technologies. They have completed 7 acquisitions over 6 years, increased their workforce to over 450 staff and continue to develop partnerships with unique collaboration models with academia, industry experts and likeminded organisations.

Mr. Stephen Tomisich, CEO of Trajan Scientific and Medical, said, “This marks an important milestone to accelerate our progress with Trajan Nutrition, and more broadly, with the adoption of Trajan’s microsampling technologies, a stronger focus on proactive wellness through patient-centric and delocalized healthcare.”

Mr Stephen Tomisich, CEO Trajan Scientific and Medical, Prof Steve Wesselingh, Executive Director SAHMRI, Mr Marco Baccanti, CEO Trajan Nutrition.
Photo(L-R): Mr Stephen Tomisich, CEO Trajan Scientific and Medical, Prof Steve Wesselingh, Executive Director SAHMRI, Mr Marco Baccanti, CEO Trajan Nutrition.

Download
Press release [PDF]

More information
www.trajannutrition.com
www.sahmri.org

Media contact information
Trajan Scientific and Medical
Tel: +44 (0) 1908 568 844
media@trajanscimed.com




Also in News

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More

CE mark for Trajan’s hemaPEN blood microsampling device, now available for diagnostic use across EU and UK
CE mark for Trajan’s hemaPEN blood microsampling device, now available for diagnostic use across EU and UK

May 07, 2020

Trajan Scientific and Medical has declared hemaPEN compliance with EU IVD Directive 98/79/EC, and its release for in vitro diagnostic use in the EU and UK. This follows the hemaPEN’s recent addition to the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class 1 IVD device.

Read More